KIT is an inclusion criterion in 18 clinical trials for gastrointestinal stromal tumor, of which 16 are open and 2 are closed. Of the trials that contain KIT status and gastrointestinal stromal tumor as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 8 are phase 2 (8 open), and 6 are phase 3 (4 open) [4].

Imatinib has evidence of efficacy in patients with KIT mutation in gastrointestinal stromal tumor [4].

KIT is an inclusion criterion in 13 clinical trials for melanoma, of which 7 are open and 6 are closed. Of the trials that contain KIT status and melanoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (1 open), 7 are phase 2 (4 open), and 1 is phase 3 (0 open) [4].

Imatinib, nilotinib, sorafenib, and sunitinib have evidence of efficacy in patients with KIT mutation in melanoma [4].

KIT is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

Dasatinib, imatinib, sorafenib, and sunitinib have evidence of efficacy in patients with KIT mutation in thymic carcinoma [4].

KIT is an inclusion criterion in 36 clinical trials for acute myeloid leukemia, of which 22 are open and 14 are closed. Of the trials that contain KIT status and acute myeloid leukemia as inclusion criteria, 11 are phase 1 (6 open), 5 are phase 1/phase 2 (4 open), 14 are phase 2 (8 open), 2 are phase 2/phase 3 (2 open), 3 are phase 3 (2 open), and 1 is no phase specified (0 open) [4].

KIT is an inclusion criterion in 22 clinical trials for myelodysplastic syndromes, of which 13 are open and 9 are closed. Of the trials that contain KIT status and myelodysplastic syndromes as inclusion criteria, 11 are phase 1 (6 open), 1 is phase 1/phase 2 (1 open), 8 are phase 2 (5 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [4].

KIT is an inclusion criterion in 16 clinical trials for malignant solid tumor, of which 12 are open and 4 are closed. Of the trials that contain KIT status and malignant solid tumor as inclusion criteria, 7 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), and 8 are phase 2 (7 open) [4].

KIT is an inclusion criterion in 14 clinical trials for acute lymphoblastic leukemia, of which 8 are open and 6 are closed. Of the trials that contain KIT status and acute lymphoblastic leukemia as inclusion criteria, 6 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (3 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [4].

KIT is an inclusion criterion in 11 clinical trials for chronic myeloid leukemia, of which 7 are open and 4 are closed. Of the trials that contain KIT status and chronic myeloid leukemia as inclusion criteria, 5 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (2 open), and 1 is no phase specified (0 open) [4].

KIT is an inclusion criterion in 10 clinical trials for multiple myeloma, of which 7 are open and 3 are closed. Of the trials that contain KIT status and multiple myeloma as inclusion criteria, 5 are phase 1 (3 open), 4 are phase 2 (4 open), and 1 is no phase specified (0 open) [4].

KIT is an inclusion criterion in 7 clinical trials for chronic myelomonocytic leukemia, of which 5 are open and 2 are closed. Of the trials that contain KIT status and chronic myelomonocytic leukemia as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [4].

KIT is an inclusion criterion in 7 clinical trials for hodgkin lymphoma, of which 3 are open and 4 are closed. Of the trials that contain KIT status and hodgkin lymphoma as inclusion criteria, 5 are phase 1 (2 open), 1 is phase 2 (1 open), and 1 is no phase specified (0 open) [4].

KIT is an inclusion criterion in 7 clinical trials for non-small cell lung carcinoma, of which 6 are open and 1 is closed. Of the trials that contain KIT status and non-small cell lung carcinoma as inclusion criteria, 3 are phase 1 (2 open) and 4 are phase 2 (4 open) [4].

KIT is an inclusion criterion in 6 clinical trials for acute biphenotypic leukemia, of which 2 are open and 4 are closed. Of the trials that contain KIT status and acute biphenotypic leukemia as inclusion criteria, 3 are phase 1 (1 open), 2 are phase 2 (1 open), and 1 is no phase specified (0 open) [4].

KIT is an inclusion criterion in 6 clinical trials for non-hodgkin lymphoma, of which 3 are open and 3 are closed. Of the trials that contain KIT status and non-hodgkin lymphoma as inclusion criteria, 6 are phase 1 (3 open) [4].

KIT is an inclusion criterion in 5 clinical trials for chronic lymphocytic leukemia, of which 3 are open and 2 are closed. Of the trials that contain KIT status and chronic lymphocytic leukemia as inclusion criteria, 4 are phase 1 (2 open) and 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 4 clinical trials for lymphoma, of which 3 are open and 1 is closed. Of the trials that contain KIT status and lymphoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].

KIT is an inclusion criterion in 4 clinical trials for myeloproliferative neoplasm, of which 3 are open and 1 is closed. Of the trials that contain KIT status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (2 open), and 1 is no phase specified (0 open) [4].

KIT is an inclusion criterion in 3 clinical trials for acute leukemia, of which 1 is open and 2 are closed. Of the trials that contain KIT status and acute leukemia as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 2 (1 open), and 1 is no phase specified (0 open) [4].

KIT is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 2 are open and 1 is closed. Of the trials that contain KIT status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [4].

KIT is an inclusion criterion in 3 clinical trials for cancer, of which 2 are open and 1 is closed. Of the trials that contain KIT status and cancer as inclusion criteria, 1 is early phase 1 (0 open) and 2 are phase 2 (2 open) [4].

KIT is an inclusion criterion in 3 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 2 are open and 1 is closed. Of the trials that contain KIT status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 1 is no phase specified (0 open) [4].

KIT is an inclusion criterion in 3 clinical trials for double-hit lymphoma, of which 1 is open and 2 are closed. Of the trials that contain KIT status and double-hit lymphoma as inclusion criteria, 3 are phase 1 (1 open) [4].

KIT is an inclusion criterion in 3 clinical trials for myelodysplastic syndrome with excess blasts-2, of which 2 are open and 1 is closed. Of the trials that contain KIT status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 3 are phase 2 (2 open) [4].

KIT is an inclusion criterion in 3 clinical trials for myelodysplastic/myeloproliferative neoplasm, of which 2 are open and 1 is closed. Of the trials that contain KIT status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) [4].

KIT is an inclusion criterion in 3 clinical trials for pancreatic carcinoma, of which 2 are open and 1 is closed. Of the trials that contain KIT status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [4].

KIT is an inclusion criterion in 3 clinical trials for refractory anemia with excess blasts, of which 1 is open and 2 are closed. Of the trials that contain KIT status and refractory anemia with excess blasts as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (1 open) [4].

KIT is an inclusion criterion in 3 clinical trials for small lymphocytic lymphoma, of which 1 is open and 2 are closed. Of the trials that contain KIT status and small lymphocytic lymphoma as inclusion criteria, 3 are phase 1 (1 open) [4].

KIT is an inclusion criterion in 3 clinical trials for therapy-related myelodysplastic syndrome, of which 3 are open and 0 are closed. Of the trials that contain KIT status and therapy-related myelodysplastic syndrome as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain KIT status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 2 (2 open) [4].

KIT is an inclusion criterion in 2 clinical trials for anaplastic large cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and anaplastic large cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is no phase specified (0 open) [4].

KIT is an inclusion criterion in 2 clinical trials for B-cell non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 2 clinical trials for Burkitt lymphoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and Burkitt lymphoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is no phase specified (0 open) [4].

KIT is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 2 clinical trials for follicular lymphoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and follicular lymphoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is no phase specified (0 open) [4].

KIT is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KIT status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 2 clinical trials for lymphoblastic lymphoma, of which 2 are open and 0 are closed. Of the trials that contain KIT status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 2 clinical trials for lymphoplasmacytic lymphoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and lymphoplasmacytic lymphoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is no phase specified (0 open) [4].

KIT is an inclusion criterion in 2 clinical trials for mantle cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and mantle cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is no phase specified (0 open) [4].

KIT is an inclusion criterion in 2 clinical trials for marginal zone lymphoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and marginal zone lymphoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is no phase specified (0 open) [4].

KIT is an inclusion criterion in 2 clinical trials for mucosal melanoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and mucosal melanoma as inclusion criteria, 2 are phase 2 (1 open) [4].

KIT is an inclusion criterion in 2 clinical trials for myelofibrosis, of which 1 is open and 1 is closed. Of the trials that contain KIT status and myelofibrosis as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 2 clinical trials for prolymphocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain KIT status and prolymphocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) and 1 is no phase specified (0 open) [4].

KIT is an inclusion criterion in 2 clinical trials for secondary acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain KIT status and secondary acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) [4].

KIT is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain KIT status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 2 clinical trials for systemic mastocytosis, of which 2 are open and 0 are closed. Of the trials that contain KIT status and systemic mastocytosis as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2/phase 3 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for acral lentiginous melanoma, of which 0 are open and 1 is closed. Of the trial that contains KIT status and acral lentiginous melanoma as inclusion criteria, 1 is phase 2 (0 open) [4].

KIT is an inclusion criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains KIT status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for acute promyelocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains KIT status and acute promyelocytic leukemia as inclusion criteria, 1 is no phase specified (0 open) [4].

KIT is an inclusion criterion in 1 clinical trial for acute undifferentiated leukemia, of which 1 is open and 0 are closed. Of the trial that contains KIT status and acute undifferentiated leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains KIT status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is no phase specified (0 open) [4].

KIT is an inclusion criterion in 1 clinical trial for aggressive systemic mastocytosis, of which 1 is open and 0 are closed. Of the trial that contains KIT status and aggressive systemic mastocytosis as inclusion criteria, 1 is phase 1 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains KIT status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KIT is an inclusion criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains KIT status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains KIT status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KIT is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains KIT status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KIT is an inclusion criterion in 1 clinical trial for hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KIT status and hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains KIT status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

KIT is an inclusion criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains KIT status and leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for malignant germ cell tumor, of which 1 is open and 0 are closed. Of the trial that contains KIT status and malignant germ cell tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KIT status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KIT status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KIT status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KIT status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for mast cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains KIT status and mast cell leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains KIT status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

KIT is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains KIT status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is no phase specified (0 open) [4].

KIT is an inclusion criterion in 1 clinical trial for mediastinal large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains KIT status and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KIT is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains KIT status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains KIT status and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KIT status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for oropharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and penile carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for plasma cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains KIT status and plasma cell leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for refractory anemia, of which 0 are open and 1 is closed. Of the trial that contains KIT status and refractory anemia as inclusion criteria, 1 is phase 2 (0 open) [4].

KIT is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KIT status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KIT is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for small lymphocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains KIT status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

KIT is an inclusion criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains KIT status and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KIT status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains KIT status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for therapy-related chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains KIT status and therapy-related chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

KIT is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].